Edgewise Therapeutics Inc. Common Stock vs uniQure N.V. Ordinary Shares — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.04 (market cap $3.94B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: Edgewise Therapeutics Inc. Common Stock is far larger — about 2.7× uniQure N.V. Ordinary Shares's market cap, and Edgewise Therapeutics Inc. Common Stock is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| EWTX | QURE | |
|---|---|---|
Market Cap | $3.94B | $1.48B |
Volume | 810,104 | 2,488,780 |
Sector | Health | Health |
52-Week High | $48.35 | $70.59 |
52-Week Low | $14.89 | $9.03 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $3.48B | $728.62M |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →